PDCD1 and cancer: As expected, among the 10 immune-cell types analyzed, major differences in transcriptional profile were found on CD8+ T cells (Figure 6B) that showed activation of pathway (TCR receptor signaling and PD-1, PD-L1 cancer immunotherapy) and functions (immune response, expansion, function, development, quantity and cell proliferation) predictive of enhanced anti-tumor immunity in tumors with higher RvD scores.